{"id":"NCT01087762","sponsor":"UCB BIOSCIENCES GmbH","briefTitle":"Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis","officialTitle":"Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-03","primaryCompletion":"2011-10","completion":"2015-08","firstPosted":"2010-03-16","resultsPosted":"2013-12-25","lastUpdate":"2018-08-01"},"enrollment":325,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Spondyloarthropathies"],"interventions":[{"type":"BIOLOGICAL","name":"CZP 200 mg Q2W","otherNames":["Cimzia","CZP","Certolizumab Pegol"]},{"type":"BIOLOGICAL","name":"CZP 400 mg Q4W","otherNames":["Cimzia","CZP","Certolizumab Pegol"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"CZP 200 mg Q2W","type":"EXPERIMENTAL"},{"label":"CZP 400 mg Q4W","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Placebo to CZP 200 mg escape on Week 16","type":"OTHER"},{"label":"Placebo to CZP 400 mg escape on Week 16","type":"OTHER"},{"label":"Placebo to CZP 200 mg on Week 24","type":"OTHER"},{"label":"Placebo to CZP 400 mg on Week 24","type":"OTHER"}],"summary":"The study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of two dose regimens of Certolizumab Pegol (CZP) in subjects with active axial Spondyloarthritis (axial SpA).","primaryOutcome":{"measure":"Assessment in Axial Spondyloarthritis International Society 20 % (ASAS20) Response Criteria at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo (FAS)","deltaMin":38.3,"sd":null},{"arm":"CZP 200 mg Q2W (FAS)","deltaMin":57.7,"sd":null},{"arm":"CZP 400 mg Q4W (FAS)","deltaMin":63.6,"sd":null},{"arm":"CZP 200 mg Q2W and CZP 400 mg Q4W (FAS)","deltaMin":60.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.004"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":104,"countries":["United States","Argentina","Belgium","Brazil","Canada","Czechia","France","Germany","Hungary","Italy","Mexico","Netherlands","Poland","Spain","United Kingdom"]},"refs":{"pmids":["24013647","40256636","39209369","34791107","30217232","29670761","29343510","28848654","28498975","27696727","26815944","25832312"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":158},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Bronchitis","Headache","Pharyngitis"]}}